Fig. 7.

In vivo response of subcutaneous fank BxPC-3 human pancreatic cancer xenografts treated with one, three, or six doses of intratumoral (IT) engineered measles virus expressing sodium-iodide symporter gene (MV-NIS) (3.5 × 106 TCID₅₀) 2 days apart beginning day 3 after tumor cell injection. Control group mice were given three doses of IT Opti-MEM (Invitrogen). TCID₅₀ = tissue culture infective dose.

A, IT MV-NIS injection slows tumor growth in treated mice compared with control mice. Difference in tumor volume between control mice and treated mice (pooled data from 1, 3, and 6 MV-NIS–injected groups) is significant, observed starting on day 5 after IT MV-NIS injection. One (*), two (**), and three (***) asterisks denote p values < 0.05, 0.005, and 0.0005, respectively.

B, Survival curves of same mice shown in A reveal that IT MV-NIS therapy significantly extended survival time in treated mice versus control mice (p = 0.005). Number of MV-NIS injections did not affect survival.